Most people have heard the same advice for improving their metabolism: eat less and exercise more.
But what if you are already eating less because you take a GLP-1 medication? What if pain, an injury, a health issue, or a demanding schedule makes regular exercise difficult? And what if the scale is moving, but you still want better support for blood sugar, body composition, and the way your body uses energy?
That is why AMPK O-304 is getting attention.
AMPK O-304 is an emerging compound being studied for metabolic health. Instead of focusing mainly on appetite, it works with a pathway that helps your cells decide whether to store energy or use it. Early research suggests that AMPK O-304 may help the body use glucose and fat more efficiently while supporting circulation and other parts of metabolic health.
The science is still developing, but the idea is easy to understand: AMPK O-304 may help support the “energy-burning” side of metabolism, not just the “eat less” side.
What is O-304?
AMPK O-304 is an oral small-molecule compound being studied for its effects on metabolism. It is also called ATX-304 in newer research.
You may hear AMPK O-304 discussed with peptides because both are popular topics in medical weight management and longevity medicine. AMPK O-304 is not technically a peptide. What matters most to the average reader, though, is what researchers hope it may do.
AMPK O-304 activates something called AMPK. Think of AMPK as a fuel manager inside your cells. When it is active, it helps tell the body to use available energy rather than continue storing it.
Your body naturally activates AMPK during exercise and periods of lower calorie intake. AMPK O-304 is being studied because it may trigger some of those same energy-related signals, even when a person cannot exercise as often as they would like.
Why does AMPK matter for metabolism?
AMPK helps your body make better decisions about fuel. It can encourage muscle cells to take in glucose, help the body use fat for energy, and reduce some of the signals involved in making and storing new fat.
In plain English, AMPK may help with several jobs:
- Moving sugar out of the bloodstream and into cells that can use it
- Encouraging the body to use stored fat for fuel
- Supporting mitochondria, the small structures that produce energy inside your cells
- Reducing the creation of new fat in the liver
- Supporting healthy blood flow
- Helping cells clear out worn or damaged parts
This is why AMPK is often called a metabolic “master switch.” It influences several systems at once rather than focusing on only hunger or calorie intake.
What did AMPK O-304 do in human research?
AMPK O-304 has already been tested in an early human study. Adults with type 2 diabetes who were taking metformin received AMPK O-304 or a placebo for 28 days.
The people receiving AMPK O-304 showed encouraging changes in fasting blood sugar and insulin resistance. Insulin resistance means the body has to work harder than it should to move sugar from the blood into the cells. Improving that response can be an important part of better metabolic health.
Researchers also saw improvements in blood flow through small vessels and reductions in blood pressure. That is interesting because good circulation helps deliver oxygen, nutrients, insulin, and glucose where the body needs them.
This was an early, short study, so it does not answer every question. It does, however, show that AMPK O-304 produced measurable effects in people, not only in a laboratory.
Could AMPK O-304 help the body burn more fat?
Early animal research suggests that AMPK O-304 may help the body use more fat for energy. In studies involving mice with obesity, AMPK O-304 increased energy use, encouraged the body to burn fatty acids, and reduced fat buildup.
The mice were not simply eating less. The compound appeared to change how their bodies handled fuel.
That is one of the most interesting things about AMPK O-304. Many approaches to medical weight management concentrate on reducing how much energy comes in. AMPK O-304 is being explored for what happens after that energy enters the body: whether it gets stored or put to work.
Animal results do not guarantee the same result in people. But they give researchers a strong reason to study AMPK O-304 for body composition, fat metabolism, and metabolic health in future human trials.
Why are people interested in AMPK O-304 alongside GLP-1 therapy?
GLP-1 therapies and AMPK O-304 focus on different parts of metabolism.
GLP-1 medications primarily help control appetite, slow digestion, and support blood sugar regulation. For many patients, that makes it easier to eat less and feel satisfied with smaller amounts of food.
AMPK O-304 is being studied from another angle. It may help muscle, fat, liver, and other tissues use energy more effectively.
An easy way to think about it is this:
| Approach | Main area of focus |
|---|---|
| GLP-1 therapy | Helps manage appetite, fullness, digestion, and blood sugar signals |
| AMPK O-304 research | Explores how cells use glucose and fat for energy |
That creates an appealing concept. One approach may help reduce how much energy comes in, while the other may help support how the body uses energy.
AMPK O-304 has not yet been studied as a GLP-1 add-on in published clinical trials. Still, the two different pathways explain why clinicians and patients interested in comprehensive metabolic care are paying attention.
What if you cannot exercise regularly?
AMPK O-304 may be especially interesting for people who cannot exercise as often as they want.
Maybe joint pain makes long walks difficult. Maybe you are recovering from an injury. You may be dealing with fatigue, limited mobility, a chronic health issue, or a schedule that leaves very little room for the gym.
None of that means you are lazy or unwilling to work on your health.
Exercise does many things that no compound can fully copy. It strengthens muscles and bones, improves balance, conditions the heart, and supports mental health. Movement should remain part of a healthy plan whenever it is safe and realistic.
But metabolic care should meet you where you are. AMPK O-304 research raises the possibility that selected energy-related signals associated with exercise could someday be supported in another way. That could be meaningful for patients whose physical capacity is limited.
What else are researchers studying?
Researchers are also looking at how AMPK O-304 may affect the liver, circulation, and heart.
In animal studies, AMPK O-304 reduced the creation of new fat in the liver and lowered liver fat buildup. A newer study using the name ATX-304 also reported improvements in body fat, cholesterol, liver fat, and early liver scarring in mice.
Other animal findings included changes in how the heart used glucose and how much blood it pumped with each beat. In the early human study, the improvements in small-vessel circulation and blood pressure added another encouraging signal.
These findings do not mean AMPK O-304 has been proven to prevent heart or liver disease. They do suggest that its effects may reach several parts of metabolic health, which is one reason the research is so interesting.
Who may be interested in AMPK O-304?
AMPK O-304 research may be relevant if you:
- Are using GLP-1 therapy and want to understand the next generation of metabolic support
- Are concerned about insulin resistance or blood sugar
- Have difficulty exercising consistently because of pain, mobility, recovery, health, or time limitations
- Want to support body composition rather than focusing only on the number on the scale
- Feel that appetite is only one piece of your metabolic challenge
- Are interested in new options for healthy aging and metabolic resilience
This does not mean AMPK O-304 is right for every person. It means the research may speak to the goals and frustrations many patients already bring into a medical weight-management consultation.
The bigger picture: metabolism is more than appetite
The most valuable idea behind AMPK O-304 may be bigger than the compound itself.
Metabolism is not controlled by one switch. Appetite matters, but so do blood sugar, insulin response, muscle, hormones, liver health, sleep, stress, movement, and the health of your cells.
That is why a prescription by itself is rarely the whole answer.
At iRevive, we use comprehensive biomarker analysis to understand what may be slowing your progress. Our medical weight management approach considers your current medications, body composition, nutrition, hormone balance, energy, mobility, and goals. Then we build a personalized protocol and adjust it as your body responds.
For patients in Lakewood Ranch, Bradenton, Sarasota, Venice, and across Florida, this means having a clinician who can help you understand new options without losing sight of the complete picture.
AMPK O-304 offers an exciting look at where metabolic medicine may be going next. If you are using GLP-1 therapy, struggling with insulin resistance, or unable to exercise as frequently as you would like, schedule a consultation with iRevive. We can help you understand your metabolic health and identify the support that makes sense for you.
Frequently Asked Questions
Is AMPK O-304 a peptide?
No. AMPK O-304 is an oral small-molecule compound, not a peptide. It is often discussed in the same metabolic-health and longevity conversations because it targets cellular energy use.
Is AMPK O-304 the same as exercise?
No. AMPK O-304 is being studied because it activates a cellular pathway that also becomes active during exercise. It may support some energy-related signals, but it does not replace the muscle, bone, heart, balance, or mental-health benefits of movement.
Can AMPK O-304 be combined with a GLP-1 medication?
Researchers have not yet tested AMPK O-304 as a GLP-1 add-on in published human trials. The interest comes from their different roles: GLP-1 therapies focus heavily on appetite and blood sugar signals, while AMPK O-304 is being studied for how tissues use energy.
Can AMPK O-304 help with weight management?
In animal studies, AMPK O-304 increased energy use, encouraged fat burning, and reduced fat buildup. Human studies have not yet established a specific weight-management result, but the early findings support more research.
Is AMPK O-304 FDA approved?
No. AMPK O-304 is still being studied and is not currently FDA approved. It has completed an early Phase IIa human study, and further clinical development is planned.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. AMPK O-304, also called ATX-304, is investigational and is not an FDA-approved medication. iRevive does not claim to offer or prescribe AMPK O-304. Do not start, stop, or change any medication or metabolic-health protocol without consulting a qualified healthcare professional who knows your medical history. Individual needs and results vary.
References
- Steneberg P, et al. “PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.” JCI Insight, 2018. https://doi.org/10.1172/jci.insight.99114
- Holm E, et al. “AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching.” JCI Insight, 2025. https://doi.org/10.1172/jci.insight.179990
- Betagenon AB. “O304 and AMPK Activator Development.” Accessed August 7, 2026. https://betagenon.com/
